论文部分内容阅读
目的:比较亲缘单倍型造血干细胞移植（HIDT）和同胞相合造血干细胞移植（MSDT）治疗完全缓解期（CR）急性T淋巴细胞白血病（T-ALL）的疗效。方法:回顾性分析2012年5月至2017年5月间在河北燕达陆道培医院接受HIDT（81例）和MSDT（17例）的CR期T-ALL患者的临床特点和预后。结果:HIDT组、MSDT组移植后100 d Ⅱ~Ⅳ度急性GVHD发生率分别为51.9%（95%n CI 42.0%~64.0%）、29.4%（95%n CI 14.1%~61.4%）（n P=0.072），Ⅲ/Ⅳ度急性GVHD发生率分别为9.8%（95%n CI 5.1%~19.1%）、11.8%（95%n CI 3.2%~43.3%）（n P=1.000），巨细胞病毒（CMV）血症发生率分别为53.1%（95%n CI 43.3%~65.2%）、29.4%（95%n CI 14.1%~61.4%）（n P=0.115），EB病毒（EBV）血症发生率分别为35.8%（95%n CI 26.8%~47.9%）、11.8%（95%n CI 3.2%~43.3%）（n P=0.048）。HIDT、MSDT两组移植后5年总生存（OS）率分别为60.5%（95%n CI 5.4%~49.0%）、68.8%（95%n CI 11.8%~40.0%）（n P=0.315），无白血病生存（LFS）率分别为58.0%（95%n CI 5.5%~46.5%）、68.8%（95%n CI 11.8%~40.0%）（n P=0.258），累积复发率分别为16.1%（95%n CI 9.8%~26.4%）、11.8%（95%n CI 3.2%~43.3%）（n P=0.643），非复发死亡率（NRM）分别为25.9%（95%n CI 17.9%~37.5%）、19.4%（95%n CI 6.9%~54.4%）（n P=0.386）。n 结论:对于CR期T-ALL患者，当缺乏合适供者时，HIDT可作为替代选择。“,”Objective:To compare the efficacy of haplotype hematopoietic stem cell transplantation (HIDT) and sibling matched hematopoietic stem cell transplantation (MSDT) in the treatment of complete remission (CR) acute T-lymphoblastic leukemia (T-ALL) .Methods:We retrospectively analyzed the clinical characteristics and outcomes of 98 patients who underwent HSCT in Hebei Yanda Ludaopei hospital with HID (n n=81) or ISD (n n=17) between May 2012 and May 2016.n Results:The incidence of grades 2-4 and 3-4 acute-versus-host disease 100 days after HSCT were 51.9% (95% Confidence interval [n CI] 42.0%-64.0%) n vs 29.4% (95% n CI 14.1%-61.4%) (n P=0.072) and 9.8% (95% n CI 5.1%-19.1%) n vs 11.8% (95% n CI 3.2%-43.3%) (n P=1.000) for HIDT and MSDT. The 100-day cumulative incidences of CMV and EBV viremia were 53.1% (95% n CI 43.3%-65.2%) n vs 29.4% (95% n CI 14.1%-61.4%) (n P=0.115) and 35.8% (95% n CI 26.8%-47.9%) n vs11.8% (95% n CI 3.2%-43.3%) (n P=0.048) . The 5-year overall survival, leukemia-free survival, cumulative incidences of relapse, and no-relapse mortality were 60.5% (95% n CI 5.4%-49.0%) n vs 68.8% (95% n CI 11.8%-40.0%) (n P=0.315) , 58.0% (95% n CI 5.5%-46.5%) n vs 68.8% (95% n CI 11.8%-40.0%) (n P=0.258) , 16.1% (95% n CI 9.8%-26.4%) n vs 11.8% (95% n CI 3.2%-43.3%) (n P=0.643) , 25.9% (95% n CI 17.9%-37.5%) n vs 19.4% (95% n CI 6.9%-54.4%) (n P=0.386) for HIDT and MSDT, respectively.n Conclusion:HID could be a valid alternative donor for patients with T-ALL in CR lacking an identical donor.